China Takes Leading Role In Chinese Medicine Standardization With ISO
This article was originally published in PharmAsia News
Executive SummaryInterpreted as a signal that China is starting to take the lead role in the international standardization of Traditional Chinese Medicine, ISO's TCM technical committee secretariat recently settled in Shanghai
You may also be interested in...
US FDA declined stakeholder requests to remove recommendation for placebo controls from a final guidance but added qualifying language on their use ‘when feasible.’ While the agency excised language on biomarker validation from the final guidance, it reaffirmed the need for early establishment of critical quality attributes and critical process parameters.
Inclisiran's price relative to existing PCSK9 drugs will be key determinant in payer acceptance. Novartis says pricing will be within cost effectiveness range estimated by ICER.
The company said it will update investors on the path forward for zuranolone in major depressive disorder after finalizing discussions with the US FDA. It would not confirm if a meeting had taken place yet.